Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT(3) antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

PJ Hesketh, SM Grunberg, J Herrstedt, Ronald de Wit, RJ Gralla, AD Carides, A Taylor, JK Evans, KJ Horgan

Research output: Contribution to journalArticleAcademicpeer-review

80 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)354-360
Number of pages7
JournalSupportive Care in Cancer
Issue number4
Publication statusPublished - 2006

Cite this